What is QIPCM?
The Quantitative Imaging for Personalized Cancer Medicine (QIPCM) program promotes cancer research by providing services and tools to support the acquisition of robust imaging data from multi-centre clinical trials. Support services include scanner validation and QA, imaging protocol development, novel image analysis tools development, image analysis, storage, archival and remote image review.
Why use QIPCM?
Quality results from multi-center radiation oncology clinical trials require consistent and robust trial protocols capable of quantifying or eliminating differences across participating institutions and solid image analysis tools. QIPCM attempts to address these issues through 3 main aims:
- Establish a stable software platform for image reads/analysis in clinical trials with capabilities for centralized image archival and remote real-time review.
- Commission a suite of defined imaging procedures and corresponding accreditation tests for use in clinical trials.
- Establish and operate a service to implement and support robust, quantitative imaging in clinical trials.
How is QIPCM different?
QIPCM provides clinicians & researchers participating in multi-centre clinical trials with a central repository for large volume functional and dynamic imaging data as well as a set of tools to provide end-to-end testing and image analysis standards of practice.
Images from each trial site are anonymized and transferred to the central repository through a secure pipeline using RSNA’s Clinical Trial Processor. All data analysis is done server side making it robust and rapid allowing the ability to perform computationally expensive operations on very large data archives remotely with minimal end-user hardware.